Loading...
•
Sep 30, 2025
Repare Therapeutics Q3 2025 Earnings Report
Repare Therapeutics reported Q3 2025 results with revenue of $11.6 million and a return to profitability driven by its Debiopharm licensing deal.
Key Takeaways
Repare Therapeutics returned to profitability in Q3 2025 with $3.3 million in net income, driven by a $11.6 million licensing revenue from Debiopharm. Operating expenses fell significantly due to prior restructuring efforts and the out-licensing of the lunresertib program. The company also recognized a gain from the termination of a collaboration agreement. Cash and equivalents stood at $72.8 million at quarter end.
Generated $11.6 million in revenue from a licensing deal with Debiopharm for lunresertib.
Reported net income of $3.3 million, reversing a net loss of $34.4 million in the same quarter last year.
Reduced operating expenses to $13.9 million from $36.4 million YoY due to restructuring and pipeline reprioritization.
Ended the quarter with $72.8 million in cash and equivalents, providing runway into 2027.
Revenue by Geographic Location
Forward Guidance
Repare expects to maintain a minimal workforce and sufficient cash runway into 2027 as it prepares for its acquisition by XenoTherapeutics.
Positive Outlook
- Expected closing of acquisition by XenoTherapeutics in Q1 2026.
- Cash runway projected through 2027.
- Continued advancement of RP-3467 and RP-1664 clinical programs.
- Ongoing monetization of out-licensed assets including lunresertib.
- Reduction in operating expenses due to workforce downsizing.
Challenges Ahead
- Pending transaction may create operational uncertainty.
- No ongoing revenue-generating products outside of licensing deals.
- Significant reduction in workforce may limit internal R&D capacity.
- Potential delays in achieving CVR milestones post-acquisition.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...